EP3620452 - PROCESS FOR THE PREPARATION OF LENVATINIB [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 25.03.2022 Database last updated on 03.09.2024 | |
Former | The patent has been granted Status updated on 16.04.2021 | ||
Former | Grant of patent is intended Status updated on 02.12.2020 | ||
Former | Request for examination was made Status updated on 11.09.2020 | ||
Former | The application has been published Status updated on 07.02.2020 | Most recent event Tooltip | 03.05.2024 | Lapse of the patent in a contracting state New state(s): MK | published on 05.06.2024 [2024/23] | Applicant(s) | For all designated states Indena S.p.A. Viale Ortles, 12 20139 Milano / IT | [2020/17] |
Former [2020/11] | For all designated states Indena S.p.A. Viale Ortles, 12 20139 Milano / IT | ||
For all designated states UNIVERSITA' DEGLI STUDI DI MILANO Via Festa del Perdono, 7 20122 Milano / IT | Inventor(s) | 01 /
SENALDI, Luca c/o INDENA S.p.A. Viale Ortles, 12 20139 Milano / IT | 02 /
ALLEGRINI, Pietro c/o INDENA S.p.A. Viale Ortles, 12 20139 Milano / IT | 03 /
CICERI, Daniele c/o INDENA S.p.A. Viale Ortles, 12 20139 Milano / IT | 04 /
BERNARDI, Anna c/o UNIVERSITA' DEGLI STUDI DI MILANO Dipartimento di Chimica Via Golgi, 19 20139 Milano / IT | [2020/11] | Representative(s) | Bianchetti & Minoja with Trevisan & Cuonzo IPS SRL Via Plinio, 63 20129 Milano / IT | [N/P] |
Former [2020/11] | Bianchetti Bracco Minoja S.r.l. Via Plinio, 63 20129 Milano / IT | Application number, filing date | 18193196.5 | 07.09.2018 | [2020/11] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3620452 | Date: | 11.03.2020 | Language: | EN | [2020/11] | Type: | B1 Patent specification | No.: | EP3620452 | Date: | 19.05.2021 | Language: | EN | [2021/20] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 11.12.2018 | Classification | IPC: | C07D215/233 | [2020/11] | CPC: |
C07D215/233 (EP,IL,KR,US);
A61K31/47 (IL,KR);
C07B2200/13 (IL,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/42] |
Former [2020/11] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | VERFAHREN ZUR HERSTELLUNG VON LENVATINIB | [2020/11] | English: | PROCESS FOR THE PREPARATION OF LENVATINIB | [2020/11] | French: | PROCÉDÉ DE PRÉPARATION DE LENVATINIB | [2020/11] | Examination procedure | 08.09.2020 | Amendment by applicant (claims and/or description) | 08.09.2020 | Examination requested [2020/42] | 08.09.2020 | Date on which the examining division has become responsible | 03.12.2020 | Communication of intention to grant the patent | 07.04.2021 | Fee for grant paid | 07.04.2021 | Fee for publishing/printing paid | 07.04.2021 | Receipt of the translation of the claim(s) | Opposition(s) | 22.02.2022 | No opposition filed within time limit [2022/17] | Fees paid | Renewal fee | 23.09.2020 | Renewal fee patent year 03 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 19.05.2021 | CY | 19.05.2021 | EE | 19.05.2021 | HR | 19.05.2021 | LT | 19.05.2021 | LV | 19.05.2021 | MC | 19.05.2021 | MK | 19.05.2021 | RS | 19.05.2021 | SK | 19.05.2021 | SM | 19.05.2021 | BG | 19.08.2021 | LU | 07.09.2021 | IS | 19.09.2021 | [2024/23] |
Former [2023/30] | AL | 19.05.2021 | |
CY | 19.05.2021 | ||
EE | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
MC | 19.05.2021 | ||
RS | 19.05.2021 | ||
SK | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
LU | 07.09.2021 | ||
IS | 19.09.2021 | ||
Former [2022/34] | AL | 19.05.2021 | |
EE | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
MC | 19.05.2021 | ||
RS | 19.05.2021 | ||
SK | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
LU | 07.09.2021 | ||
IS | 19.09.2021 | ||
Former [2022/25] | AL | 19.05.2021 | |
EE | 19.05.2021 | ||
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
MC | 19.05.2021 | ||
RS | 19.05.2021 | ||
SK | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
IS | 19.09.2021 | ||
Former [2022/23] | EE | 19.05.2021 | |
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
RS | 19.05.2021 | ||
SK | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
IS | 19.09.2021 | ||
Former [2022/10] | EE | 19.05.2021 | |
HR | 19.05.2021 | ||
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
RS | 19.05.2021 | ||
SK | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
IS | 22.12.2021 | ||
Former [2022/07] | HR | 19.05.2021 | |
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
RS | 19.05.2021 | ||
SM | 19.05.2021 | ||
BG | 19.08.2021 | ||
IS | 19.09.2021 | ||
Former [2021/51] | HR | 19.05.2021 | |
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
RS | 19.05.2021 | ||
BG | 19.08.2021 | ||
IS | 19.09.2021 | ||
Former [2021/49] | HR | 19.05.2021 | |
LT | 19.05.2021 | ||
LV | 19.05.2021 | ||
BG | 19.08.2021 | ||
Former [2021/47] | LT | 19.05.2021 | |
BG | 19.08.2021 | ||
Former [2021/46] | LT | 19.05.2021 | Documents cited: | Search | [AD]EP1683785 (EISAI CO LTD [JP]) [AD] 1-4 * example - *; | [A]CN104876864B (BEIJING KANG LISHENG PHARMACEUTICAL TECHNOLOGY DEV CO LTD) [A] 1-4* example -; claim - *; | [A]CN106632033 (BEIJING VENTUREPHARM BIOTECH CORP) [A] 1-4 * example -; claim - * | by applicant | WO0232872 | US7683172 | CN107266363 |